FDA Authorizes First Oral COVID-19 Post-Exposure Prevention Medication

The U.S. Food and Drug Administration has granted approval for XOCOVA® (ensitrelvir), an oral antiviral drug, for use as post-exposure prophylaxis against COVID-19. This marks a significant development, offering the first oral treatment option for individuals aged 12 and older to prevent infection after exposure to the virus. The approval addresses a crucial need in current COVID-19 prevention strategies.